Edwards Lifesciences is expected to post Q1 2026 revenue of $1.58 billion and earnings per share of $0.72, while the stock currently trades at $89.45 against a $105.00 average price target.
The central story for this quarter is the scaling of the Transcatheter Mitral and Tricuspid Therapies (TMTT) division, specifically the market adoption of the EVOQUE tricuspid valve.
Following the divestiture of the Critical Care unit, management's focus has shifted entirely to high-growth structural heart innovation. Analysts are specifically looking for evidence that the flagship TAVR franchise can maintain high single-digit growth amidst intensifying global competition.